Almirall Highlights Breakthrough Dermatology Evidence and Innovation at EADV 2025

At the 34th Congress of the European Academy of Dermatology and Venereology (EADV) , Almirall, SA (ALM), a global biopharmaceutical company specializing in medical dermatology, is consolidating its position as a key player. The company will present highlights from its portfolio, including new evidence for lebrikizumab in atopic dermatitis, results for tildrakizumab in plaque psoriasis, and tirbanibulin in actinic keratosis.

In total, Almirall is contributing 44 scientific abstracts to the congress, two international symposia, and an interactive space aimed at supporting healthcare professionals in therapeutic decision-making. The presentations cover highly prevalent dermatological conditions such as atopic dermatitis (AD), psoriasis (PSO), actinic keratosis (AK), and hidradenitis suppurativa (HS).

“Our commitment to dermatology goes beyond innovation. We place the patient at the center of everything we do, and the clinical evidence we presented at the EADV is proof that our treatments not only transform their quality of life but also add value to daily clinical practice,” said José Cabrera, senior director of medical affairs at Almirall.

Atopic Dermatitis: Almirall brings evidence from Real-World Practice

Almirall presents the interim results of the ADlife study, the first real-world clinical trial with lebrikizumab. With 100 patients treated for 16 weeks, high efficacy was confirmed from week 4, along with a consistent safety profile. These findings demonstrate that the efficacy of the pivotal trials translates to the routine clinical setting, even in complex populations.

The ADjoin long-term extension trial demonstrates that improvements achieved at week 16 are maintained over two years of continued treatment. Patients also reported sustained improvements in itch and sleep quality, as assessed by the POEM questionnaire, for up to three years.

For its part, the ADvantage study, a pioneer in using the WHO-5 well-being index, reveals that the treatment significantly improves the psychological health of patients, reaching levels comparable to the healthy population in just 16 weeks and maintaining them until week 525.

The results of the ADvocate 1 and 2 trials reinforce the efficacy of lebrikizumab by demonstrating high rates of skin clearance and itch relief from week 4, with effects maintained up to one year of follow-up.

“Atopic dermatitis profoundly impacts a patient’s emotional and social life. Evidence from real-life settings confirms that the benefits of clinical trials are also reflected in more complex populations. Furthermore, data on psychological well-being underscore the need for a comprehensive approach that considers all aspects of the disease,” said Pablo de la Cueva, vice president of the organization department of the AEDV.

In addition, during the congress, Almirall is organizing the symposium “Long-term control in atopic dermatitis: raising the therapeutic target ,” chaired by Professor Sébastien Barbarot (France), with the participation of international experts from Germany, the United Kingdom, and Italy.

Psoriasis: results in difficult-to-treat areas

The ZODIPSO and CzATCH clinical practice studies demonstrate the efficacy of tildrakizumab in difficult-to-treat sites such as nails, scalp, and genital areas. 7–10 The TIL-SENIOR study analyzes the treatment profile in older patients, while TIL-TWO demonstrates benefits in patients with high body weight or high disease burden.

The PROCARE-T study highlights the high level of patient and professional satisfaction with this treatment in the multidisciplinary management of psoriasis. PRO-SCALP also confirms that CAL/BPD PAD™ cream improves symptoms in mild-to-moderate scalp psoriasis and contributes to emotional well-being.

“These results show that we don’t just treat the skin, but also improve the patient’s overall well-being and daily life. The evidence in specific populations and critical areas reinforces the need for a personalized and multidisciplinary approach,” said Anna López, Hospital de la Santa Creu i Sant Pau in Barcelona.

The symposium “Psoriasis: Is There Anything Left to Do?” , chaired by Professor Jo Lambert (Belgium), will bring together European experts to discuss unmet needs and future challenges.

R&D Pipeline: New Options for QA and HS

The TirbAKare trial confirms the suitability of tirbanibulin for treating large areas of up to 100 cm² affected by AK, with a significant reduction in lesions compared to placebo and a favorable safety profile.

In the Late-Breaker category , Almirall presents Phase I results of LAD191 , a monoclonal antibody against IL-1RAP for hidradenitis suppurativa. The data show favorable safety and tolerability, along with early signs of clinical efficacy.

Likewise, at its booth at the congress, Almirall will offer healthcare professionals interactive content and educational resources on dermatological innovation and patient needs.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in GACETA MEDICA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.